The stock of Marker Therapeutics Inc (NASDAQ:MRKR) registered an increase of 14.97% in short interest. MRKR’s total short interest was 2.05 million shares in March as published by FINRA. Its up 14.97% from 1.79 million shares, reported previously. With 240,000 shares average volume, it will take short sellers 9 days to cover their MRKR’s short positions. The short interest to Marker Therapeutics Inc’s float is 8.2%.
The stock increased 9.53% or $0.51 during the last trading session, reaching $5.86. About 232,206 shares traded. Marker Therapeutics, Inc. (NASDAQ:MRKR) has risen 96.23% since March 17, 2018 and is uptrending. It has outperformed by 91.86% the S&P500.
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development of next-generation T cell immunotherapies for the treatment of hematological malignancies and solid tumor indications. The company has market cap of $265.87 million. The Company’s cell therapy technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. It currently has negative earnings. The firm is also advancing various peptide- and gene immuno-therapeutics for the treatment of cancer and metastatic disease, including its Folate Receptor Alpha program for breast and ovarian cancers and HER2/neu+ peptide antigen program (TPIV100/110) in Phase II clinical trials.
More notable recent Marker Therapeutics, Inc. (NASDAQ:MRKR) news were published by: Nasdaq.com which released: “Atossa Genetics Announces FDA Approval of Oral Endoxifen for â€œExpanded Accessâ€ as Post-Mastectomy Treatment for a US Breast Cancer Patient – Nasdaq” on March 14, 2019, also Nasdaq.com with their article: “Could An ETF Be The First Milestone Of Bitcoin’s Second Decade? – Nasdaq” published on March 06, 2019, Nasdaq.com published: “Immutep Presents Positive IMP761 Preclinical Results at 14th Congress of European Crohn’s and Colitis Organisation – Nasdaq” on March 07, 2019. More interesting news about Marker Therapeutics, Inc. (NASDAQ:MRKR) were released by: Prnewswire.com and their article: “Marker Therapeutics Announces Clinical Update at the Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR 2019 – PRNewswire” published on February 25, 2019 as well as Benzinga.com‘s news article titled: “54 Stocks Moving In Tuesday’s Mid-Day Session – Benzinga” with publication date: February 19, 2019.